Cyclo Therapeutics Inc

Company Profile

Cyclo Therapeutics Inc had its IPO on 2020-12-09 under the ticker symbol CYTHW.

The company operates in the sector and industry. Cyclo Therapeutics Inc has a staff strength of 5 employees.

Stock update

Shares of Cyclo Therapeutics Inc opened at $0.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.37 - $0.37, and closed at $0.37.

This is a 0% increase from the previous day's closing price.

A total volume of 100 shares were traded at the close of the day’s session.

In the last one week, shares of Cyclo Therapeutics Inc have increased by +26.21%.

Cyclo Therapeutics Inc's Key Ratios

Cyclo Therapeutics Inc has a market cap of $62.76 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Cyclo Therapeutics Inc’s revenue was $985153 with a gross profit of $0 and an EBITDA of $-8907030. The EBITDA ratio measures Cyclo Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cyclo Therapeutics Inc’s operating margin was -905.22% while its return on assets stood at -111.53% with a return of equity of -15702.91%.

In Q1, Cyclo Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.2%.

Cyclo Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cyclo Therapeutics Inc’s profitability.

Cyclo Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Cyclo Therapeutics Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$4.10 million

Total Liabilities

$4.50 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Cyclo Therapeutics Inc ended 2024 with $4.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.10 million while shareholder equity stood at $-438876.00.

Cyclo Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.50 million in other current liabilities, 1056.00 in common stock, $-68806464.00 in retained earnings and $0 in goodwill. Its cash balance stood at $915176.00 and cash and short-term investments were $915176.00. The company’s total short-term debt was $16,969 while long-term debt stood at $0.

Cyclo Therapeutics Inc’s total current assets stands at $3.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $131224.00 compared to accounts payable of $4.48 million and inventory worth $244497.00.

In 2024, Cyclo Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Cyclo Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.37

52-Week High

$1.1

52-Week Low

$0.16

Analyst Target Price

$

Cyclo Therapeutics Inc stock is currently trading at $0.37 per share. It touched a 52-week high of $1.1 and a 52-week low of $1.1. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.36 and 200-day moving average was $0.35 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.